Best Molecular Diagnostics

Molecular diagnostics platforms are essential tools in modern healthcare, enabling the detection and analysis of genetic material to diagnose diseases, monitor treatment responses, and guide personalized medicine. As of February 2026, several leading companies offer advanced molecular diagnostics solutions:

F. Hoffmann-La Roche Ltd.
A global leader in molecular diagnostics, Roche provides comprehensive solutions, including PCR-based tests and next-generation sequencing platforms for oncology, infectious diseases, and genetic disorders. (skyquestt.com)

Hologic, Inc.
Specializing in women's health, Hologic offers molecular diagnostics assays for HPV, STIs, and breast cancer, utilizing advanced technologies for accurate and timely results. (skyquestt.com)

Abbott Laboratories
Abbott provides molecular diagnostics platforms for infectious diseases, oncology, and point-of-care testing, focusing on rapid and reliable diagnostic solutions. (skyquestt.com)

Illumina, Inc.
Illumina is renowned for its next-generation sequencing systems and reagents, offering comprehensive genomic research and clinical diagnostics tools. (skyquestt.com)

Thermo Fisher Scientific Inc.
Thermo Fisher delivers comprehensive diagnostics solutions, including molecular assays, laboratory instruments, and reagents, supporting a wide range of applications. (skyquestt.com)

These companies are at the forefront of molecular diagnostics, continually innovating to provide accurate, efficient, and accessible diagnostic solutions across various medical fields.

Based on the latest market research and industry reports, here are the best molecular diagnostics platforms currently available:

Top Established Platforms

Leading Market Players

The top five players in the molecular diagnostics market are Danaher Corporation (US), F. Hoffmann-La Roche Ltd. (Switzerland), Illumina, Inc. (US), bioMérieux (France), and Hologic, Inc. (US)

1. Illumina Platforms

Illumina, Inc. (US) is prominent in the molecular diagnostics market, supported by its leadership in next-generation sequencing (NGS) technologies.

Illumina offers a broad portfolio of FDA- and CE-cleared products that support a range of clinical applications, including oncology, reproductive health, rare genetic disorders, and infectious disease testing.

2. Roche Diagnostics

Roche's expertise spans from molecular diagnostics to clinical chemistry, making them a key player in advancing precision medicine.

Roche leverages its extensive diagnostics infrastructure and high-throughput molecular platforms to deliver reliable solutions across clinical settings.

3. Cepheid GeneXpert System

Cepheid's GeneXpert System is one of the most flexible platform in the world that provides healthcare professionals best-in0class test menu for a variety of settings including laboratory testing to near-patient applications.

Cepheid specializes in molecular diagnostics, particularly in the rapid and accurate detection of infectious diseases. Their GeneXpert system is widely used for point-of-care testing, providing timely results for critical infections.

4. Abbott Diagnostics

Their solutions encompass core laboratory testing, point-of-care diagnostics, and molecular diagnostics.

5. Thermo Fisher Scientific

Thermo Fisher Scientific is a scientific research company with a significant presence in life sciences and diagnostics. They provide a wide array of analytical instruments, reagents, consumables, software, and services.

Emerging and Innovative Platforms

CRISPR-Based Diagnostics

CRISPR Diagnostics Ltd. specializes in developing next-generation CRISPR-based point-of-care platforms for infectious disease detection. The companys microfluidics-integrated systems enable multiplexed, high-throughput CRISPR assays with quick turnaround times

Caspr Biotech develops portable CRISPR-Cas diagnostic devices for rapid and accurate detection of infectious pathogens. Its field-deployable diagnostic kits are designed to operate in resource-limited settings, providing high specificity and affordability.

Other Notable Platforms

QIAGEN

In June 2025, Tracer Biotechnologies announced a strategic partnership with QIAGEN to co-develop and commercialize minimal residual disease (MRD) assays for solid tumors on QIAGEN's QIAcuity digital PCR platform.

Agilent Technologies

Agilent offers a broad portfolio of next-generation sequencing (NGS) products that enable generation of reliable data. Agilent SureSelect hybridization capture-based reagents include custom and catalog kits for preparation of molecular libraries and target enrichment.

Market Outlook

The global molecular diagnostics market, valued at US$18.29 billion in 2024, stood at US$19.48 billion in 2025 and is projected to advance at a resilient CAGR of 9.6% from 2025 to 2030, culminating in a forecasted valuation of US$30.74 billion by the end of the period.

The best platforms combine high accuracy, rapid turnaround times, broad test menus, and scalability from point-of-care to high-throughput laboratory settings. The market is increasingly moving toward precision medicine applications, with emerging CRISPR-based technologies showing particular promise for rapid, portable diagnostics.

Several platforms stand out in the field of molecular diagnostics, each offering unique advantages:

• Abbott's i-STAT System: This handheld device provides lab-quality results within minutes at the patient's bedside, making it invaluable in critical care settings. It can perform a broad range of tests, including those for blood gas, electrolytes, chemistries, hematology, and cardiac markers.
• Roche's cobas® Liat® System: A fully automated platform for molecular diagnostics, it specializes in detecting infectious diseases like influenza, Strep A, and SARS-CoV-2, delivering results in approximately 20 minutes.
• Cepheid GeneXpert System: Known for speed and reliability, this system offers a comprehensive test menu covering a wide range of infectious diseases, such as tuberculosis, HIV, and respiratory viruses, with results available in under an hour.
• Quidel Sofia® 2 Fluorescent Immunoassay Analyzer: This platform uses advanced fluorescent technology for rapid and accurate diagnosis of conditions like influenza, RSV, and Group A Streptococcus.
• BD Veritor™ System: Plays a significant role in point-of-care diagnostics, particularly for infectious diseases.

Other companies in the molecular diagnostics market include:

• Danaher Corporation
• F. Hoffmann-La Roche Ltd
• Illumina, Inc
• bioMérieux
• Hologic, Inc
• Thermo Fisher Scientific Inc
• QIAGEN
• Myriad Genetics
• GoPath Laboratories

The best molecular diagnostics platforms depend on the specific application, but leading options include GeneXpert systems (Cepheid), cobas systems (Roche), TaqPath assays (Thermo Fisher Scientific), and next-generation sequencing platforms (Illumina).

Established Market Leaders

Abbott, Thermo Fisher Scientific, Danaher, and Roche dominate the molecular diagnostics market. Key platforms from these companies include:

• Cepheid's GeneXpert systems: Automated cartridge-based NAAT (nucleic acid amplification test) systems available in multiple configurations (Infinity, IV, XVI) for infectious diseases, genetic diseases, respiratory conditions, and oncology.
• Roche's cobas systems: PCR-based NAT systems for infectious diseases, respiratory diseases, and sexual health, plus the LightCycler® PRO qPCR system for cardiovascular, gastrointestinal, and women's health applications.
• Thermo Fisher Scientific: Offers TaqPath diagnostic assays and real-time PCR master mixes for molecular testing.
• Illumina: A world leader in DNA sequencing and array-based technologies with platforms increasingly applied in clinical diagnostics for oncology, rare diseases, and reproductive health.

Emerging Innovations

Newer platforms focus on point-of-care testing and AI integration. Notable startups include:

• Karius: Uses next-generation sequencing to detect over 1,250 pathogens through cell-free DNA analysis in blood, with results within one business day.
• Detechgene: Develops portable molecular diagnostic platforms for on-site pathogen testing with visual readout.
• Aignostics: Offers AI-driven analysis of tumor microenvironment in histopathology images.

The choice of platform should align with your specific diagnostic needs, testing volume, and infrastructure capabilities.